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Malaria was estimated to result in 214 million clinical casesand 438,000 deaths in 2015, primarily in children under
5 years of age. In Africa, malaria causes approximately 10% of all
deaths in children under 5 years of age. The RTS,S/AS01 malaria
vaccine has been tested in young children in phase III clinical trials
and shown to be 18 to 36% efficacious against clinical malaria (1).
Although the vaccinemay be efficacious against clinicalmalaria, it
does not however reduce overall mortality.
The World Health Organization (WHO) recently published
a position paper on malaria vaccines (2), with emphasis on the
RTS,S/AS01 vaccine. Although the vaccine has had modest effi-
cacy, the data in Table 1 show that RTS,S was associated with
higher all-cause mortality in girls (mortality ratio, 1.91; 95% con-
fidence interval [CI], 1.30 to 2.79; P  0.0006) but not in boys
(mortality ratio, 0.84; 95% CI, 0.61 to 1.17; P  0.3343) in both
age groups in which the vaccine was tested (i.e., 6 to 12 weeks and
5 to 17months) (http://www.gsk-clinicalstudyregister.com/files2/
9a7b7726-34e2-418d-bea6-c3fb071fd51c). The sex-differential
effect is highly significant (P 0.001). There also was a tendency
for RTS,S to be associatedwith a higher risk of fatalmalaria in girls
(malaria mortality ratio, 1.90 [0.82 to 4.37]) but not in boys (ma-
laria mortality ratio, 1.07 [0.52 to 2.18]). It is counterintuitive
that there was no reduction in fatal malaria associated with
RTS,S; however, RTS,S was associated with a twofold-higher
case fatality ratio in children who got severe malaria (3).
The WHO has speculated that the increased mortality in girls
was “largely due to the low female mortality in the control arm”
and “could be due to chance” (2), despite the P value of 0.0006 for
girls and a mortality rate after RTS,S of 2.4% in girls compared to
1.8% in boys (risk ratio, 1.33 [1.02 to 1.74]) (Table 2). Although
theWHO could be correct in speculating that this finding was due
to chance, these numbers suggest a need for caution and addi-
tional research. Before RTS,S is introduced into routine vaccina-
tion schedules, we should determine whether RTS,S/AS01 in-
creases mortality in girls and investigate possible mechanisms.
There is precedent for the observation that infant girls experi-
ence increased mortality following receipt of vaccines. For exam-
ple, in the 1980s, when the high-titer measles vaccine (HTMV)
was introduced to prevent measles in children under 9 months
of age, there was a twofold increase in all-cause mortality in
girls, but no increase in boys, which led to withdrawal of the
vaccine (4). It was subsequently determined that the increased
mortality occurred only among girls who received diphtheria-
tetanus-pertussis (DTP) vaccine after HTMV and not among
girls who received HTMV after their last dose of DTP (5). The
interaction between HTMV and DTPmay have caused nonspe-
cific negative effects on all-cause mortality in girls but not boys.
Evidence from multiple studies of nonlive vaccines, including
DTP and the inactivated polio vaccine (IPV), show that these
nonlive vaccines have greater detrimental effects for girls than
boys (5, 6). Therefore, the increased female mortality after RTS,S/
AS01 should not be dismissed as an unexpected finding that oc-
curred by chance. Further clinical studies should explore whether
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TABLE 1 RTS,S malaria vaccine and mortality by sex
Sex and age
of group
No. of deaths overall [no. of deaths due to malaria]/no. of persons in group (%)
RTS,S recipient/control
risk ratio (95% CI)R3Ra R3Cb
R3R and R3C groups
combined C3Cc
Males
5–17 mo 26 [4]/1,509 (1.7) 19 [9]/1,472 (1.3) 45 [13]/2,981 (1.5) 29 [8]/1,471 (2.0) 0.77 (0.48–1.22)
6–12 wk 24 [3]/1,116 (2.2) 26 [8]/1,118 (2.3) 50 [11]/2,234 (2.2) 26 [3]/1,079 (2.4) 0.93 (0.58–1.48)
Total 95 [24]/5,215 (1.8) 55 [11]/2,550 (2.2) 0.84 (0.61–1.17)
Females
5–17 mo 35 [9]/1,467 (2.4) 32 [8]/1,500 (2.1) 67 [17]/2,967 (2.3) 17 [4]/1,503 (1.1) 2.00 (1.18–3.39)
6–12 wk 27 [5]/1,064 (2.5) 29 [4]/1,060 (2.7) 56 [9]/2,124 (2.6) 16 [3]/1,100 (1.5) 1.81 (1.04–3.14)
Total 123 [26]/5,091 (2.4) 33 [7]/2,603 (1.3) 1.91 (1.30–2.79)
a R3R, 3 RTS,S plus booster RTS,S.
b R3C, 3 RTS,S plus comparator vaccine.
c C3C, controls (comparator vaccines).
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girls need lower doses of the RTS,S/AS01 vaccine or should receive
the vaccine with or separately from other vaccines or at different
ages than boys.
Preclinical studies in animal models can help provide insights
into the biological basis of these observations, but here too, anal-
ysis of potential sex effects has been lacking. Published studies of
RTS,S or recombinant circumsporizoite protein inmice and non-
human primates have only reported using adult females or have
not reported the sex of the animals (7–9). Generally, in the fields of
immunology, vaccinology, and infectious diseases, investigators
either do not report the sex of their animals or predominately use
female animals (10). This “one size fits all” approach to vaccine
research is not working. Preclinical studies should consider how
both age and sex affect vaccine responses and outcomes. RTS,S
vaccine could also be used to uncover immunological mecha-
nisms for a possible increase in mortality after RTS,S vaccination
among girls but not boys.
The RTS,S vaccine is modestly effective at reducing clinical
malaria in children, but the sex differences in all-cause mortality
should be rigorously studied in both clinical trials and experimen-
tal animalmodels, particularly in light of prior experiencewith the
HTMV. We seek to raise awareness about the need for additional
research into how the RTS,S vaccine and, possibly, other vaccines
are associatedwith greatermortality in girls but not boys. This will
only be achieved if age and sex are considered in a priori hypoth-
eses in vaccine trials to identify and address potential risks early in
the vaccine development process.
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TABLE 2 Female-male mortality risk ratio in RTS,S malaria vaccine
recipients
Age group
Female/male risk ratio (95% CI)
R3Ra R3Cb R3R and R3C combined
5–17 mo 1.38 (0.84–2.29) 1.65 (0.94–2.90) 1.50 (1.03–2.18)
6–12 wk 1.18 (0.69–2.03) 1.18 (0.70–1.98) 1.18 (0.81–1.72)
Total 1.33 (1.02–1.74)
a R3R, 3 RTS,S plus booster RTS,S.
b R3C, 3 RTS,S plus comparator vaccine.
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